Clinical Trial Search

Primary: Number of Participants With Adverse Events — 6; 2; 3; 5 Participants

Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 252 participants

Primary: Time to Progression — 11.3; 9; 15.6; 4.5 months

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants

Primary: Change in Insulin Net Incremental Area-Under-The-Curve (iAUC) — 80559.3; 78707.3; 64270.8 pmol/L/min

Primary: Preference Question: How Would You Say These Contact Lenses Compare Overall With the Contact Lenses You Usually Use? — 195; 93; 92 Participants

Primary: Isokinetic Muscle Strength Test of the More and Less Affected Knees — 110.48; 141.05; 123.02; 127.83 Newton/meter

Primary: Assessment of Pre-implementation, Post-implementation With Decision Coaching, and Post-implementation Without Decision Coaching — 235; 45; 106; 51 Participants

Primary: Convenience PACT-Q2 Scores at Second and Last Assessment Compared to Baseline Assessment — 19.23; 23.08 Unit on scale — p=< 0.0001

Primary: Composite Cognitive Score — 45.5; 47.9 units on a scale

Primary: Change From Baseline in FEV1 AUC0-6 — 0.266; 0.203; 0.282; 0.240 Liters

Primary: Pain Relief Expressed as Total Pain Relief (TOTPAR) Over the 4 Hours Post-dose Period (TOTPAR4) — 9.9; 8.6; 5.4; 5.8 units on a scale — p=<0.0001

Primary: Specific Image-Based Airway Volume (siVaw) — 1.11; 1.23 ratio — p=0.0187

Primary: Change From Baseline to Week 12 in Weekly Vomiting Episodes — 5.7; 7.7; 6.9; 4.8 vomiting episodes per week — p=0.36